Prenatal Antibody Titers by ID-MTS™ Gel Test

Explore the clinical outcomes associated with performing titration studies with the ID-MTS Gel Test method.

Oct 13, 2019
main-image

Duration: 19 minutes

Hemolytic disease of the fetus and newborn (HDFN) is a blood disorder that occurs when a mother’s blood type is incompatible with that of her unborn child. Titration studies are an aspect of the standard of care for perinatal evaluation of patients who have become alloimmunized with an antibody of potential clinical significance in HDFN. Variability across gel and tube testing methods as well as the interpretation of clinical outcomes based on titration endpoints pose a challenging situation.nnBy automating testing, more consistent results can be delivered, providing a reliable tool for physicians to recommend the most appropriate treatment. Dr. Cooling reviews clinical evidence comparing manual and automated gel testing including a study correlating HDFN severity to critical values.

Disclosures: This promotional educational activity is brought to you by Ortho Clinical Diagnostics and is not certified for Continuing Medical Education (CME). The speakers are presenting on behalf of Ortho Clinical Diagnostics and must present information in accordance with applicable and/or local regulatory country requirements.

About Our Speaker:
s-card-img
About Our Speaker:

Laura Cooling, MD, MS

University of Michigan Medical School, Ann

Arbor, Michigan

Dr. Cooling received a BS, a MSc from the University of Iowa and an MD from the University of Iowa Medical School. She completed her residence training in Laboratory Medicine followed by a Fellowship in Transfusion Medicine and Pathology at the University of Iowa Hospitals and Clinics. Upon completion of her training, Dr. Cooling served as a Clinical Associate in the Department of Pathology at the University of Iowa Hospitals and Clinics and later as Assistant Professor at State University of New York Health Science Center at Syracuse. She accepted a position as Clinical Assistant Professor at the University of Michigan Medical School in 2000. Dr. Cooling serves as Associate Director of the Department of Pathology's Blood Bank & Transfusion Service. Dr. Cooling is board certified in Clinical Pathology and Transfusion Medicine. She participated in the first study comparing the current tube method with the gel method, which was presented at AABB in 2001.

Dr. Cooling received a BS, a MSc from the University of Iowa and an MD from the University of Iowa Medical School. She completed her residence training in Laboratory Medicine followed by a Fellowship in Transfusion Medicine and Pathology at the University of Iowa Hospitals and Clinics. Upon completion of her training, Dr. Cooling served as a Clinical Associate in the Department of Pathology at the University of Iowa Hospitals and Clinics and later as Assistant Professor at State University of New York Health Science Center at Syracuse. She accepted a position as Clinical Assistant Professor at the University of Michigan Medical School in 2000. Dr. Cooling serves as Associate Director of the Department of Pathology's Blood Bank & Transfusion Service. Dr. Cooling is board certified in Clinical Pathology and Transfusion Medicine. She participated in the first study comparing the current tube method with the gel method, which was presented at AABB in 2001.